CM Life Sciences, Inc. Unit
CMLFU
CMLFU was delisted on the 22nd of July, 2021.
58 hedge funds and large institutions have $420M invested in CM Life Sciences, Inc. Unit in 2020 Q3 according to their latest regulatory filings, with 58 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SHCM
Sachem Head Capital Management
New York
|
+$36.5M |
| 2 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$33.7M |
| 3 |
Millennium Management
New York
|
+$27.7M |
| 4 |
BCM
BlueCrest Capital Management
St Helier,
Jersey
|
+$26.3M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$22.6M |
Top Sellers
CMLFU Hedge Fund Activity: Q3 2020 in Review
58 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in CM Life Sciences, Inc. Unit (CMLFU) for Q3 2020, worth a combined $420M.
Buyers outnumbered sellers: 58 funds opened new CMLFU positions and 0 closed out — a net gain of 58 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Sachem Head Capital Management, opening a new position worth an estimated $36.5M.
- 58 institutional investors held CM Life Sciences, Inc. Unit (CMLFU) as of Q3 2020, up from 0 in Q2 2020.
- Funds reported $420M of CM Life Sciences, Inc. Unit stock for Q3 2020.
- 58 funds opened new CM Life Sciences, Inc. Unit positions in Q3 2020 and 0 closed out, a net change of +58 holders.
- The largest CM Life Sciences, Inc. Unit buyer in Q3 2020 was Sachem Head Capital Management, an estimated $36.5M added.
Based on aggregated 13F filings for Q3 2020.